A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE

por Yanofsky, R, Abduallah, Y, Golovics, P, Lakatos, P L, Bitton, A, Wild, G, Afif, W, Bessissow, T
Publicado 2022

A143 SAFETY OF BIOLOGICAL THERAPIES IN ELDERLY IBD: A SYSTEMATIC REVIEW

por Golovics, P, Drügg Hahn, G, Wetwittayakhlang, P, Wild, G, Afif, W, Bitton, A, Bessissow, T, Lakatos, P L
Publicado 2022

A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

por Wetwittayakhlang, P, Albader, F, Golovics, P, Drügg Hahn, G, Bessissow, T, Bitton, A, Afif, W, Wild, G, Lakatos, P L
Publicado 2022

A191 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

por Kablawi, D, Aljohani, F, Palumbo, C S, Restellini, S, Bitton, A, Wild, G, Afif, W, Lakatos, P L, Bessissow, T, Sebastiani, G
Publicado 2023

The management of iron deficiency in inflammatory bowel disease – an online tool developed by the RAND/UCLA appropriateness method

por Reinisch, W, Chowers, Y, Danese, S, Dignass, A, Gomollón, F, Haagen Nielsen, O, Lakatos, P L, Lees, C W, Lindgren, S, Lukas, M, Mantzaris, G J, Michetti, P, Moum, B, Peyrin-Biroulet, L, Toruner, M, Woude, J, Weiss, G, Stoevelaar, H
Publicado 2013